{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:34Z","timestamp":1792003534453,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ad.2016.12.017","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T14:15:54Z","timestamp":1489673754000},"page":"506-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Psoriasis e h\u00edgado graso no alcoh\u00f3lico"],"prefix":"10.1016","volume":"108","author":[{"given":"J.M.","family":"Carrascosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bonanad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dauden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Olveira-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.12.017_bib0305","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2016.12.017_bib0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2016.12.017_bib0315","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0320","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","article-title":"Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C","volume":"24","author":"Yatsuji","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0325","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4254\/wjh.v7.i10.1297","article-title":"Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets","volume":"7","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2016.12.017_bib0335","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1478-3231.2006.01311.x","article-title":"The prevalence of primary non-alcoholic fatty liver disease in a population based study and its association with biochemical and anthropometric measures","volume":"26","author":"Zelber-Sagi","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.ad.2016.12.017_bib0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2016.12.017_bib0345","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/TP.0b013e31828d1588","article-title":"Steatosis among living liver donors without evidence of fatty liver on ultrasonography: Potential implications for preoperative liver biopsy","volume":"95","author":"Ahn","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.ad.2016.12.017_bib0350","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2016.12.017_bib0355","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1056\/NEJM200004273421707","article-title":"Evaluation of abnormal liver-enzyme results in asymptomatic patients","volume":"342","author":"Pratt","year":"2000","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ad.2016.12.017_bib0360","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2016.12.017_bib0365","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0370","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ad.2016.12.017_bib0375","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A Noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.ad.2016.12.017_bib0380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"Castera","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0385","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0390","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ad.2016.12.017_bib0395","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ad.2016.12.017_bib0400","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1756283X15593700","article-title":"Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis","volume":"9","author":"Shen","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.ad.2016.12.017_bib0405","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2016.12.017_bib0410","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ebmed-2011-100388","article-title":"Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis","volume":"17","author":"Malhotra","year":"2012","journal-title":"Evid Based Med"},{"key":"10.1016\/j.ad.2016.12.017_bib0415","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2036.2009.04230.x","article-title":"Review article: Omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease","volume":"31","author":"Masterton","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ad.2016.12.017_bib0420","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ad.2016.12.017_bib0425","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0430","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0435","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study","volume":"70","author":"Van der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0440","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0445","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","article-title":"Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis","volume":"298","author":"Sommer","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2016.12.017_bib0450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/apt.13042","article-title":"The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic","volume":"41","author":"Roberts","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2016.12.017_bib0455","first-page":"1","article-title":"Integrated approach to comorbidity in patients with psoriasis","volume":"103","author":"Daud\u00e9n","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2016.12.017_bib0460","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.12.017_bib0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.ad.2016.12.017_bib0470","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jdv.12208","article-title":"BIOBADADERM Study Group. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry","volume":"28","author":"Carrascosa","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2016.12.017_bib0475","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.trsl.2014.06.008","article-title":"Obesity and the liver: Nonalcoholic fatty liver disease","volume":"164","author":"Koppe","year":"2014","journal-title":"Transl Res"},{"key":"10.1016\/j.ad.2016.12.017_bib0480","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose tissue as an endocrine organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ad.2016.12.017_bib0485","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4254\/wjh.v7.i3.315","article-title":"Non-alcoholic fatty liver disease and psoriasis: So far, so near","volume":"27","author":"Ganzetti","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ad.2016.12.017_bib0495","first-page":"1454","article-title":"Drug use and toxicity in psoriatic disease: Focus on methotrexate","volume":"35","author":"Taylor","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0500","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-4632.2011.05436.x","article-title":"A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia","volume":"52","author":"Ng","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0505","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1478-3231.2007.01489.x","article-title":"Biochemical andbiophysical assessment of MTX-induced liver fibrosis in psoriasispatients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis","volume":"27","author":"Berends","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.ad.2016.12.017_bib0510","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-3083.2010.03841.x","article-title":"Psoriasis and non-alcoholicfatty liver disease","volume":"25","author":"Wenk","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2016.12.017_bib0515","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/01480545.2010.483519","article-title":"Effects of erdosteine on cyclosporine-A-induced hepatotoxicityin rats","volume":"34","author":"Erarslan","year":"2011","journal-title":"Drug Chem Toxicol"},{"key":"10.1016\/j.ad.2016.12.017_bib0520","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tox.2013.01.020","article-title":"Acitretin affects bioenergetics of liver mitochondriaand promotes mitochondrial permeability transition: Potential mechanisms of hepatotoxicity","volume":"306","author":"Silva","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.ad.2016.12.017_bib0525","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/egh.11.17","article-title":"Relevance of TNF-alfa gene polymorphisms in nonalcoholic fatty liver disease","volume":"5","author":"Tilg","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0530","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12291-012-0236-5","article-title":"Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression","volume":"28","author":"Zahran","year":"2013","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.ad.2016.12.017_bib0535","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10753-007-9053-z","article-title":"The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"31","author":"Koca","year":"2008","journal-title":"Inflammation"},{"issue":"Suppl 1","key":"10.1016\/j.ad.2016.12.017_bib0540","first-page":"167","article-title":"A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis","volume":"25","author":"Yalcin","year":"2014","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.ad.2016.12.017_bib0545","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00535-012-0678-9","article-title":"The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis","volume":"48","author":"Campanati","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ad.2016.12.017_bib0550","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1055\/s-2008-1027411","article-title":"Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH)","volume":"46","author":"Schramm","year":"2008","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.ad.2016.12.017_bib0555","first-page":"P013","article-title":"Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients","volume":"24","author":"Vilarrasa","year":"2010","journal-title":"JEADV."},{"key":"10.1016\/j.ad.2016.12.017_bib0560","first-page":"667","article-title":"Adiponectin as an anti-inflammatory factor in thepathogenesis of psoriasis: Induction of elevated serum adiponectinlevels following therapy","volume":"164","author":"Shibata","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0565","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/ijd.12706","article-title":"Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-\u03b1 inhibitors: Results of a retrospective analysis","volume":"54","author":"Campanati","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0570","first-page":"1004","article-title":"Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis","volume":"114","author":"Cauza","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ad.2016.12.017_bib0575","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/09546634.2013.848260","article-title":"Cardiometabolic biomarkers in chronicplaque psoriasis before and after etanercept treatment","volume":"25","author":"Puig","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2016.12.017_bib0580","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1177\/039463200702000408","article-title":"Effect of etanercepton insulin sensitivity in nine patients with psoriasis","volume":"20","author":"Marra","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2016.12.017_bib0585","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated withinfliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2016.12.017_bib0590","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index inpatients with chronic plaque psoriasis: A prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2016.12.017_bib0595","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ad.2015.02.002","article-title":"Liver injury in psoriasis patients receiving ustekinumab: A retrospective study of 44 patients treated in the clinical practice setting","volume":"106","author":"Llamas-Velasco","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2016.12.017_bib0600","unstructured":"Ficha t\u00e9cnica del producto [consultado 20 Jul 2016]. Disponible en: http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR__Product_Information\/human\/003729\/WC500183129.pdf"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017300674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017300674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:06:12Z","timestamp":1757552772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731017300674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0001731017300674"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.12.017","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis e h\u00edgado graso no alcoh\u00f3lico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}